視網膜生物製劑市場 - 按藥物類別適應症、配銷通路、全球預測

在視網膜疾病盛行率不斷上升的推動下，2024-2032 年視網膜生物製品市場規模將以 8.2% 的複合年成長率成長。據 Oural Therapeutix 稱，全球估計有 4.016 億人受到各種形式的視網膜疾病的影響。老年性黃斑部病變 (AMD)、糖尿病視網膜病變和視網膜靜脈阻塞等疾病正變得越來越常見，這主要是由於全球人口老化以及糖尿病和高血壓發病率的上升。視網膜生物製劑以其先進的治療能力提供了有針對性和有效的治療選擇。

生物技術的創新使得能夠創造出專門針對視網膜疾病根本原因的新型治療方法。與傳統療法相比，這些新的生物療法提供了更高的療效和安全性，為患有糖尿病視網膜病變等疾病的患者帶來了顯著的益處。正在進行的研究和臨床試驗繼續解決未滿足的醫療需求並擴大治療領域。

視網膜生物製品產業根據藥品類別、適應症、配銷通路和地區進行分類。

TNF-a 抑制劑部分將在 2032 年獲得關注，因為它們透過阻斷腫瘤壞死因子-α (TNF-a) 蛋白發揮作用。這些抑制劑在減少發炎和阻止糖尿病視網膜病變和葡萄膜炎等疾病的進展方面顯示出顯著的功效。 TNF-a 抑制劑在保護視力和防止進一步視網膜損傷方面的有效性使其成為視網膜疾病治療手段的寶貴補充。

到 2032 年，線上藥局市場將快速成長，因為人們可以輕鬆獲得各種生物療法藥物，包括治療視網膜疾病的藥物，而且價格往往具有競爭力。送貨上門的便利性，加上線上諮詢醫療保健專業人員的能力，使得網路藥局成為對病人有吸引力的選擇。 COVID-19 大流行加速了向線上購買的轉變，許多患者選擇數位管道以避免親自去藥局。隨著越來越多的消費者習慣線上購物以滿足他們的醫療保健需求，這一趨勢預計將持續下去。

在完善的醫療基礎設施和高額醫療支出的推動下，歐洲視網膜生物製品市場規模將在 2032 年之前穩步擴張。該地區人口老化導致視網膜疾病盛行率不斷上升，對有效治療產生了巨大需求。德國、英國、法國和義大利等國家在採用先進視網膜生物製劑方面處於領先地位，並得到強力的監管框架和旨在改善眼睛健康的政府舉措的支持。此外，歐洲擁有多家領先的製藥公司和研究機構，積極參與視網膜生物製劑的開發和商業化。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 視網膜疾病盛行率增加
    • 與視網膜生物製劑相關的研發活動不斷增加
    • 生物療法的進展
  • 產業陷阱與挑戰
    • 嚴格的監管要求
    • 潛在不利影響的風險
• 成長潛力分析
• 監管環境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• VEGF-A拮抗劑
• TNF-α抑制劑

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 黃斑部病變
• 糖尿病性視網膜病變
• 葡萄膜炎
• 其他適應症

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• AbbVie Inc.
• Amgen Inc.
• Janssen Pharmaceuticals (Johnson & Johnson)
• F-Hoffman La Roche Ltd.
• Oxurion NV
• Novartis AG
• MeiraGTx Limited
• Regeneron Pharmaceuticals Inc.
• OncoGene Pharmaceuticals
• SemaThera Inc.

The Retinal Biologics Market size will grow at 8.2% CAGR during 2024-2032, driven by the increasing prevalence of retinal disorders. According to Ocular Therapeutix, an estimated 401.6 million people worldwide are affected by various forms of retinal disease. Conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion are becoming more common, largely due to an aging global population and the rising incidence of diabetes and hypertension. Retinal biologics, with their advanced therapeutic capabilities offer targeted and efficient treatment options.

Innovations in biotechnology have enabled the creation of novel treatments that specifically target the underlying causes of retinal diseases. These new biologic therapies offer improved efficacy and safety profiles compared to traditional treatments, providing significant benefits for patients with conditions like diabetic retinopathy. Ongoing research and clinical trials continue to address unmet medical needs and expand the therapeutic landscape.

The retinal biologics industry is classified based on drug class, indication, distribution channel, and region.

The TNF-a inhibitors segment will gain traction through 2032, as they work by blocking the tumor necrosis factor-alpha (TNF-a) protein. These inhibitors have shown significant efficacy in reducing inflammation and halting the progression of diseases such as diabetic retinopathy and uveitis. The effectiveness of TNF-a inhibitors in preserving vision and preventing further retinal damage makes them a valuable addition to the therapeutic arsenal for retinal disorders.

The online pharmacies segment will grow rapidly through 2032, owing to the easy access to a wide range of biologic treatments, including those for retinal disorders, often at competitive prices. The convenience of home delivery, coupled with the ability to consult healthcare professionals online, is making online pharmacies an attractive option for patients. The COVID-19 pandemic has accelerated the shift towards online purchasing, with many patients opting for digital channels to avoid in-person visits to pharmacies. This trend is expected to continue as more consumers become comfortable with online shopping for their healthcare needs.

Europe retinal biologics market size will expand at a steady pace through 2032, driven by a well-established healthcare infrastructure and high medical spending. The region's aging population is contributing to an increasing prevalence of retinal disorders, creating a substantial demand for effective treatments. Countries such as Germany, the United Kingdom, France, and Italy are at the forefront of adopting advanced retinal biologics, supported by strong regulatory frameworks and government initiatives aimed at improving eye health. Additionally, Europe is home to several leading pharmaceutical companies and research institutions that are actively involved in the development and commercialization of retinal biologics.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of retinal diseases
    • 3.2.1.2 Rising research & development activities related to retinal biologics
    • 3.2.1.3 Advancements in biologic therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 Risk of potential adverse effects
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 VEGF-A antagonist
• 5.3 TNF-a inhibitor

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Macular degeneration
• 6.3 Diabetic retinopathy
• 6.4 Uveitis
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 Janssen Pharmaceuticals (Johnson & Johnson)
• 9.4 F-Hoffman La Roche Ltd.
• 9.5 Oxurion NV
• 9.6 Novartis AG
• 9.7 MeiraGTx Limited
• 9.8 Regeneron Pharmaceuticals Inc.
• 9.9 OncoGene Pharmaceuticals
• 9.10 SemaThera Inc.